PerspectiveTransplantation and Autoimmune Disease

Regulatory T Cells: Customizing for the Clinic

See allHide authors and affiliations

Science Translational Medicine  18 May 2011:
Vol. 3, Issue 83, pp. 83ps19
DOI: 10.1126/scitranslmed.3001819

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Immune-suppressive cellular immunotherapy requires large numbers of antigen-specific regulatory T cells (Treg cells), lymphocytes that suppress certain immune responses. Together, three papers in this issue of Science Translational Medicine describe protocols for the ex vivo expansion of human Treg cells and assess the immune-suppressive function of ex vivo–manipulated Treg cells after transfer into humanized mouse disease models. Along with recent phase I clinical trial results, these new data provide a platform for clinical use of Treg cells as personalized therapeutic agents for the treatment of autoimmune diseases, graft-versus-host disease, and transplant rejection.


  • Citation: X. Wang, L. Lu, S. Jiang, Regulatory T Cells: Customizing for the Clinic. Sci. Transl. Med. 3, 83ps19 (2011).

View Full Text

Stay Connected to Science Translational Medicine